245.64

0.71% 2.03

Resmed Inc (RMD)

Overview News Price History Option Chain Financials Why RMD Down? Discussions Forecast Stock Split Dividend History

Resmed Inc stock is traded at $245.64, with a volume of 422.26K. It is up +0.71% in the last 24 hours and up +4.86% over the past month. ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Previous Close:

$243.61

Open:

$243.61

24h Volume:

422.26K

Relative Volume:

0.44

Market Cap:

$35.79B

Revenue:

$4.81B

Net Income/Loss:

$1.11B

P/E Ratio:

39.88

EPS:

6.16

Net Cash Flow:

$1.35B

1W Performance:

+0.38%

1M Performance:

+4.86%

6M Performance:

+13.07%

1Y Performance:

+60.55%

1-Day Range:

$241.28

$245.53

1-Week Range:

$240.53

$247.75

52-Week Range:

$140.81

$260.49

Resmed Inc Stock (RMD) Company Profile

Name

Resmed Inc

Sector

Healthcare (1181)

Industry

Medical Instruments & Supplies (58)

Phone

(858) 746-2400

Address

9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA

Employee

10,140

Twitter

@resmed

Next Earnings Date

2024-10-24

Latest SEC Filings

RMD's Discussions on Twitter

Resmed Inc Stock (RMD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-06-24	Resumed	KeyBanc Capital Markets	Overweight
Oct-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Oct-12-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Oct-09-23	Upgrade	JP Morgan	Neutral → Overweight
Sep-29-23	Downgrade	Wolfe Research	Outperform → Peer Perform
Sep-06-23	Upgrade	Needham	Hold → Buy
Sep-05-23	Downgrade	UBS	Buy → Neutral
Aug-01-23	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
May-23-23	Initiated	UBS	Buy
Apr-14-23	Initiated	Mizuho	Buy
Jan-17-23	Upgrade	JP Morgan	Neutral → Overweight
Oct-28-22	Downgrade	Citigroup	Buy → Neutral
Oct-20-22	Upgrade	BofA Securities	Neutral → Buy
Oct-12-22	Initiated	Jefferies	Hold
Sep-08-22	Upgrade	Citigroup	Neutral → Buy
Aug-15-22	Downgrade	CLSA	Buy → Outperform
Aug-12-22	Downgrade	Citigroup	Buy → Neutral
Aug-12-22	Downgrade	JP Morgan	Overweight → Neutral
Aug-12-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jun-06-22	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Apr-06-22	Initiated	Wolfe Research	Outperform
Jan-31-22	Upgrade	Citigroup	Neutral → Buy
Jan-31-22	Upgrade	Goldman	Neutral → Buy
Jan-28-22	Upgrade	RBC Capital Mkts	Underperform → Sector Perform
Jan-24-22	Upgrade	BofA Securities	Underperform → Neutral
Jan-24-22	Upgrade	JP Morgan	Neutral → Overweight
Jan-13-22	Upgrade	CLSA	Outperform → Buy
Jan-13-22	Upgrade	Robert W. Baird	Neutral → Outperform
Dec-21-21	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight
Dec-06-21	Upgrade	Macquarie	Neutral → Outperform
Oct-22-21	Upgrade	CLSA	Underperform → Outperform
Aug-02-21	Downgrade	CLSA	Outperform → Sell
Aug-02-21	Downgrade	Needham	Buy → Hold
Jul-28-21	Upgrade	Jefferies	Underperform → Hold
Jul-26-21	Downgrade	JP Morgan	Overweight → Neutral
Jul-14-21	Initiated	RBC Capital Mkts	Underperform
Jun-28-21	Downgrade	Citigroup	Buy → Neutral
Jun-22-21	Upgrade	Macquarie	Neutral → Outperform
Jun-22-21	Initiated	Robert W. Baird	Neutral
Jun-21-21	Reiterated	Needham	Buy
Jun-16-21	Downgrade	BofA Securities	Neutral → Underperform
Jun-09-21	Upgrade	CLSA	Sell → Outperform
May-21-21	Upgrade	JP Morgan	Neutral → Overweight
May-11-21	Upgrade	Citigroup	Neutral → Buy
Apr-30-21	Downgrade	Citigroup	Buy → Neutral
Mar-16-21	Upgrade	Needham	Hold → Buy
Nov-02-20	Upgrade	UBS	Neutral → Buy
Oct-30-20	Upgrade	JP Morgan	Underweight → Neutral
Oct-27-20	Upgrade	BofA Securities	Underperform → Neutral
Aug-07-20	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-17-20	Upgrade	Morgan Stanley	Equal-Weight → Overweight
May-01-20	Downgrade	JP Morgan	Neutral → Underweight
May-01-20	Upgrade	Oppenheimer	Perform → Outperform
Feb-18-20	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-03-20	Initiated	CLSA	Underperform
Jan-31-20	Downgrade	UBS	Buy → Neutral
Jan-10-20	Initiated	Oppenheimer	Perform
Nov-22-19	Initiated	KeyBanc Capital Markets	Sector Weight
Jul-29-19	Upgrade	UBS	Neutral → Buy
Jul-16-19	Downgrade	UBS	Buy → Neutral
May-06-19	Upgrade	UBS	Neutral → Buy
Apr-18-19	Upgrade	JP Morgan	Underweight → Neutral
Jan-25-19	Downgrade	Goldman	Buy → Neutral
Jan-25-19	Downgrade	JP Morgan	Neutral → Underweight
Oct-26-18	Upgrade	Credit Suisse	Neutral → Outperform
Jul-02-18	Initiated	Goldman	Buy